Maybe not, but investors historically on the value side are now buying more stocks on the growth side of the market. But should they be?
The Japanese conglomerate's investment in a company whose CEO's business dealings are under fire won't derail its continuing success: Opinion.
Acquisitions are a zero-sum game: both buyer and seller need to feel they are getting a good deal. Unfortunately, buyers usually pay too much.
The drug distributor will remain a value stock despite some perceived threats, including the White House's aim to restructure pharmaceutical pricing.
Beating earnings estimates quarter after quarter doesn't have much to do with long-term shareholder value.
Count the reasons why Apple's near-term financial future doesn't look too bright.
Investor relations professionals should prepare for what's eventually inevitable: a reversion to the mean for stock prices.
For CFOs wanting to understand investor behavior, here's an argument that Jeff Bezos is human, after all, and Amazon can't defy basic economic principles.
Will Elon Musk succeed with his strategy of wooing investors with promises for the future and one shiny new object after another?
Forget it. No one knows what the stock market will do in the short term, and if someone says they do, they're a liar.
If oil prices remain at current levels, at some point bond investors may no longer be willing to support the shrinking enterprise.
The idea that the online retail-distribution giant could overtake large entrenched drug distributors like McKesson is far-fetched.
